- TRADE NAME: Zejula (Tesaro)
- INDICATIONS: Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
- CLASS: Poly (ADP-ribose) polymerase (PARP) inhibitor
- HALF-LIFE: 36 hours
- FDA APPROVAL DATE: 03/27/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/06/2025
